Jasper Therapeutics

IPO

Public · Redwood City, United States · $181.0M raised

Headquarters
Redwood City
Total Funding
$181.0M
Last Round
$132.0M Private EquityAug 2026
Rounds
3
Type
Public
Ticker
JSPR · NASDAQ

About

Jasper Therapeutics is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117), as a therapeutic to deplete mast cells and treat chronic mast cell diseases such as chronic urticaria and asthma. The company is currently conducting clinical studies of briquilimab in patients with CSU or CIndU, and is planning to initiate a clinical study in asthma patients. To date, briquilimab has demonstrated an efficacy and safety profile in over 160 dosed subjects and healthy volunteers.

Summary

Jasper Therapeutics is a Biotech company based in Redwood City, United States. It has raised $181.0M in total across 3 rounds, most recently a $132.0M Private Equity round in Aug 2026. Investors include Roche Venture Fund, Abingworth Bioventures and Alexandria Venture Investments.

Funding History

Private EquityPrivate EquityAug 2026
$132.0M

Sign up to see all 3 rounds

Series A through Private Equity — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Jasper Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/jasper-therapeutics"><img src="https://indexed.vc/api/badge/company/jasper-therapeutics" alt="Jasper Therapeutics on Indexed.vc" width="260" height="76" /></a>